WELCOME TO

THE EORTC CLTG 2022 MEETING

September, 22nd – 24 th, 2022

WELCOME

Dear friends and colleagues,

It is our great pleasure to organize the next EORT CLTG meeting in Madrid, 22-24 September 2022, on the theme “Cutaneous lymphomas: from molecules to PROs”.

We would like to thank the board of the EORTC CTLG for giving us this opportunity. It is a great honor, we are extremely happy and very excited with this task.

The EORTC CLTG Annual Meeting has been a major event for the scientific community all across Europe and it is constantly evolving, becoming more popular, innovative and influential, while maintaining high standards of scientific quality and family atmosphere.

We plan to organize a meeting including everything related to cutaneous lymphomas, from molecules to patient reported outcomes. We would like to have the latest advances in basic and translational research, the latest data originated from PROCLIPI, the latest novelties in treatment. Very importantly, we will include a session for patients at the end of the meeting.

Besides that, we would like to organize a meeting very comfortable for delegates and attendants, plenty of social interaction, plenty of friendship and maybe with some fun. Please, come to Madrid to present your work, your data, your research; come to Madrid to learn, to teach, to enjoy.

We look forward to welcoming you to Madrid in September 2022.

 

Julia Scarisbrick, EORTC CLTG Chair
Pablo L Ortiz Romero, Chair of the EORTC CLTG meeting 2022 in Madrid.

COMMITTEES

EORTC CLTG

Julia Scarisbrick, Chair
Evangelia Papadavid, Secretary
Emmanuella Guenova, Treasurer

Conference Organizing Committee

Pablo L Ortiz Romero
Jose Luis Rodríguez Peralto
Concepción Postigo Llorente
Daniel Falkenhain
Cristina Vico Alonso
Eloy Tarín Vicente
Alba Sánchez Velázquez
Margarita Sánchez-Beato
María S. Rodríguez Pinilla
Marta Rodriguez Moreno
Ruth Alonso

Scientific committee

Chalid Assaf
Martine Bagot
Emilio Berti
Marie Beylot – Barry
Antonio Cozzio
Teresa Estrach
Ricardo Fernández de Misa
Fernando Gallardo
Emmanuella Guenova
Emmilia Hodak
Werner Kempf
Claus-Detlev Klemke
Robert Knobler
Mercedes Morillo

Cristina Muniesa
Jan Nicolay
Pablo Luis Ortiz Romero
Evangelia Papadavid
Ramón Pujol
Pietro Quaglino
Annamari Ranki
Octavio Servitje
Rudolf Stadler
Franz Trautinger
Maarten Vermeer
Sean Whittaker
Rein Willemze

GENERAL INFORMATION

Purpose

The goal is to offer a comprehensive conference to present new research, share experiences, and discuss new directions or the advancement of knowledge in Cutaneous Lymphomas.

Who attends this meeting 

The conference is designed for international dermatologists, basic scientists, epidemiologists, hematologists, immunologists, oncologists, pathologists, radiation oncologists, and psychologists.
The program committee expects 200-300 attendees. The participation of students and post-doctoral fellows is encouraged through reduced registration fees, oral presentations, and poster sessions.
A session dedicated to patients will be organized on Saturday afternoon in partnership with the newly stablished Spanish Assotiation of Cutaneous Lymphoma Patients.

Conference Focus

The conference will present sessions covering all aspects of cutaneous lymphomas including:

  • Pathophysiology, Genomics and Epigenomics, Molecular targets
  • Immunology, Host response, Animal models, Microenvironment
  • Translational Research, diagnostic and prognostic markers
  • Pathology
  • Epidemiology
  • PROCLIPI research
  • New treatments, clinical trials, topical and systemic therapies, combination of treatments, therapeutic strategies
  • Non MF T-cell lymphoma, B cell lymphoma
  • Quality of Life and Patient Reported outcomes.

A preliminary program will be available end of summer

Program at a glance

  • Thursday, 22 September
  • Friday, 23 September
  • Saturday, 24 September
Hotel Only You Atocha
8:00h – 9:00h
EORTC BOARD MEETING
Chairs: J Scarisbrick, E Guenova, E Papadavid
***Closed meeting, only under invitation
9:00h – 10:00h
Breakup meeting UV treatments for cutaneous lymphoma
Chairs: S Whittaker, J Latzka
***Closed meeting, only under invitation
10:00h – 11:00h
EUROFLOW MEETING
Chairs: M Vermeer, S Najidh
***Closed meeting, only under invitation
11:00h – 12:00h
Patch/plaque project
Chairs: J Scarisbrick, P Quaglino. M Bagot, E Hodak
***Closed meeting, only under invitation
12:00h Transfer Only You Atocha Hotel – Hospital
Hospital
13:00h Lunch at Hospital
13:30h Opening Ceremonyl
Dra. Carmen Martínez de Pancorbo
Prof. Julia Scarisbrick
Dr. Pablo L. Ortiz
13:30h

14:30h
INDUSTRY SYMPOSIUM: HELSINN
A multi-level analysis of chlormethine: from skin cells to clinical cases
Chair Co-Chair
Pablo Ortiz-Romero
Hospital 12 de Octubre, Universidad Complutense, Madrid Medical School,Madrid, Spain
Emmanuella Guenova
University Hospital Zürich,University of Lausanne,Lausanne, Switzerland
Objectives
To summarize the data available regarding the mechanism of action of chlormethine (CL) gel, and discuss its potential use as a combination therapy for patients with mycosis fungoides (MF)
13:30 – 13:35 Opening and welcome Pablo Ortiz-Romero
13:35 – 13:50 The skin level: Release, permeation, and pharmacokinetics of chlormethine (CL) gel
Pablo Ortiz-Romero
13:50 – 14:05 The molecular level: The mode of action of CL gel and impact on T cells
Emmanuella Guenova
14:05 – 14:15 The patient level: An expert interview on how to utilise CL gel in real clinical practice
Emmanuella Guenova, interviewed by Pablo Ortiz-Romero
14:15 – 14:25 Interactive Q&A session
Emmanuella Guenova and Pablo Ortiz-Romero, moderated by Pablo Ortiz-Romero
14:25 – 14:30 Closing remarks
Pablo Ortiz-Romero
14:30h

15:30
Oral Presentations 01. Biologic insights
Chairs: M Vermeer, M Bagot, Joan Guitart
14:30h BioIns-O-01 Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: A European Multicenter Study
S Najih
14:42h BioIns-O-02 Targeting immunosuppressive macrophages in the cutaneous T-cell lymphoma microenvironment.
CP Portocarrero
14:54h BioIns-O-03 Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.
CP Tensen
15:06h BioIns-O-04 POT1 gene dysfunction in Primary Cutaneous T-cell Lymphoma.
DR Bakr
15:18h BioIns-O-05 Dual blocking of CD47 and PD-L1 increases innate and adaptive immune responses in CTCL.
D. Weiner & S. Talluru
15:30h Coffee Break
16:00h

17:00h
Oral Presentations 2. Biologic insights
Chairs: Y kim, JP Merlio. E Guenova
16:00 BioIns-O-06 Single-cell RNA sequencing reveals race-based heterogeneity of malignant T-cells and skin microenvironment in patients with cutaneous T-cell lymphoma.
C Querfeld
16:12 BioIns-O-07 Mycosis Fungoides: molecular identity revealed by nanostring analysis.
RAA Alonso Alonso
16:24 BioIns-O-08 Single-cell RNA sequencing analyses of primary cutaneous B-cell disorders reveal distinct molecular patterns consistent with clinical behavior.
JG Griss
16:36 BioIns-O-09 Risk of progre
ssion of early-stage mycosis fungoides from RNA analysis.
V Gargallo Moneva
16:48 BioIns-O-10 Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukemic cutaneous T-cell lymphoma patients.
YCT Tsai
17:00h

18:00h
Oral Presentations 3. Biologic insights
Chairs: R Willemze, J Choi, F Gallardo
17:00h BioIns-O-11 Combination of JAKi and MAPKi exerts antiangionenic potential in Cutaneous T-cell Lymphoma.
FK Karagianni Fani
17:12h BioIns-O-12 Cutaneous Lymphocyte Antigen (CLA) is a potential therapeutic target in Cutaneous T Cell Lymphoma.
S Poglio
17:24h BioIns-O-13 Proliferative tumor infiltrating lymphocytes within microenvironment impact prognosis in cutaneous B-cell lymphomas.
APL Pham-Ledard
17:36h BioIns-O-14 Use of the T Cell receptor B-chain constant domains 1 and 2 (TCRBC1 and TCRBC2) studies for the analysis of T-Cell clonality.
RAA Alonso Alonso
17:48h BioIns-O-15 CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.
A De Masson
18:00h

19:00h
Oral Presentations 4. Histopathology
Chairs: M Battistella, A Gru, W Kempf
18:00h Hist-O-01 Artificial intelligence-assisted probability scoring for differentiation of early mycosis fungoides and benign inflammatory dermatoses on H&E-stained pathology slides of skin biopsies.
T Doeleman
18:12h Hist-O-02 Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: an EORTC-CLG/ISCL survey.
G Roccuzzo
18:24h Hist-O-03 Different subtypes of lymphomatoid papulosis are more overlapping than expected – an analysis of published histologic patterns and criteria.
T Fricke
18:36h Hist-O-04 Aggressive cytotoxic dermal lymphomas of the earlobe: a single-institution case series.
DR Guitart
18:48h Hist-O-05 Histiocytoid Sweet’s Syndrome in a patient with myelodysplastic syndrome with multilineage dysplasia (MDS-MLD), and monoclonal gammopathy of undetermined significance (MGUS) IgG kappa type.
O Pavlova
19:00h Poster session 1. Poster walk.
Selected authors should be present to explain their posters
19:30h COCKTAIL AND GET TOGETHER
20:15h Transfer Hospital – Only You Atocha Hotel
8:00h Transfer Only You Atocha Hotel – Hospital
8:30h

9:30h
INDUSTRY SYMPOSIUM: Therakos. Malinkrodt
08:30 – 08:55 ECP in the current International Guidelines & Clinical update
Speaker TBA
08:55 – 09:20 Role of ECP in the management of CTCL – Spanish experience
Speaker TBA
09:20 – 09:30 Q&A
9:30h
Guest lecture 1
MA Piris. Fundación Jiménez Díaz, Madrid

Cutaneous Lymphoma Diagnosis: tools and goals
Chair: PL Ortiz Romero, J Scarisbrick
10:15h
Guest lecture 2:
Manuel Serrano. Institute for Reserach in Biomedicine (IRB), Barcelona.

Cellular senescence and its impotance in cancer therapy
Chair: PL Ortiz Romero, J Scarisbrick
11:00h Coffee Break
11:30h

13:00h
Oral Presentations 05.
Clinical and Pre-clinical studies.

Chair: R Cowan, Ch Assad, E Papadavid
11:30h Clin-O-01 Investigating clinical characteristics and outcomes of hypopigmented mycosis fungoides: retrospective review at a single tertiary referral center.
ST Talluru
11:42h Clin-O-02 Early versus Advanced stage folliculotropic micosis fungoides survival analysis in a reference latinamerican center.
HCPC Pérez Cely
11:54h PreClin-O-01 Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome.
FA AMATORE
12:06h PreClin-O-02 First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type.
JM Merlio
12:18h PreClin-O-03 ICOSL: a new diagnostic marker and a new therapeutic target using an ICOS-Fc construct in Sézary syndrome?
JG GIUSTINIANI
12:30h PreClin-O-04 Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate, SGN-CD70A, in patient-derived xenograft models.
WA Ai Zhuang
12:42h PreClin-O-05 Evaluation of the role of different cell populations and immune regulators in Mycosis Fungoides microenvironment.
AP Pavlidis
13:00h Lunch
13:30h

14:30h
INDUSTRY SYMPOSIUM :  KYOWA KIRIN
How does targeted therapy affect immune dysfunction in mycosis fungoides and Sézary syndrome?
13:30h – 13:35h Welcome and introduction
Professor Pablo Ortiz-Romero
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
13:35h – 13:40 The tumour microenvironment in MF and SS
Professor Martine Bagot
Department of Dermatology and Inserm U976 chez Hôpital Saint Louis, Paris, France
13:40 – 13:55h Effect of mogamulizumab ▼ on the tumour microenvironment and anti-tumour immunity
Dr Hélène Moins-Teisserenc
Department of Hematology, Université de Paris, Institut de Recherche Saint-Louis, Paris, France
13:55 – 14:10h Presentation and mechanisms of mogamulizumab-associated rash
Professor Maxime Battistella
Department of Dermatopathology, Hopital Saint Louis, Paris, France
14:10 – 14:20h Case studies
Professor Martine Bagot and Professor Maxime Battistella
14:20 – 14:30h Q&A and close
POTELIGEO® (mogamulizumab) Prescribing Information can be found via the QR code:

▼ This medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are encouraged to report suspected adverse reactions.
This activity is developed and funded by Kyowa Kirin International PLC – All rights reserved.
KKI/INT/MOG/0636
Date of preparation: July 2022

14:30h

15:30h
Oral Presentations 6.
Preclinical Studies

Chairs: Sean Whittaker, Jan Nicolai, R Pujol
14:30h BioIns-O-16 Digital quantitative detection of DNA methylation biomarkers: A helpful tool in the early diagnosis of Sézary syndrome.
WH Zoutman
14:42h BioIns-O-17 In vivo modelling of Cutaneous T-cell lymphoma: The role of SOCS1.
Y LUO
14:54h BioIns-O-18 A 9-gene prognostic signature for predicting survival outcome in mycosis fungoides.
S Alberti-Violetti
15:06h BioIns-O-19 Molecular crosstalk between PLC?1 and STAT3 in Cutaneous T-Cell Lymphoma.
V R Campbell
15:18h BioIns-O-20 Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues.
AG Gros Audrey
15:30h Coffee Break
16:00h

17:00h
Oral Presentations 7.
Therapeutics

Chair E Hodak, P Quaglino, O Servitje
16:00h Ther-O-01 Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: Stage 1 results from the TELLOMAK phase 2 trial.
MM Marianna Muller
16:12h Ther-O-02 The COBALT-LYM Study of CTX130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients with Relapsed/Refractory (R/R) T-Cell Malignancies.
DR Zain
16:24h Ther-O-03 Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-cell Lymphomas.
DR Mou
16:36h Ther-O-04 Dimethyl fumarate (DMF) therapy in CTCL – final results from a clinical phase II study.
JP Nicolay
16:48h Ther-O-05 Clinical outcomes of single-agent chemotherapy in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
DW Weiner
17:00h

18:00h
Oral Presentations 8.
Therapeutics

Chair C Querfeld, A Cozzio, R Stadler
17:00h Ther-O-06 Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced CTCL.
MO Mathias
17:12h Ther-O-07 Combination Therapy With Chlormethine Gel and Narrow-Band Ultraviolet B for Patients With Mycosis Fungoides: A Case Series.
L Gleason
17:24h Ther-O-08 Broad-band ultraviolet A combined with narrow-band ultraviolet B: an effective modality for early folliculotropic mycosis fungoides and early mycosis fungoides refractory to narrow-band ultraviolet B.
I Amitay-Laish
17:36h Ther-O-09 New type of Mogamulizumab induced rash simulating Lupus miliaris disseminatus faciei.
C Mitteldorf
17:48h Ther-O-10 Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas. An EORTC CLTF study.
KM Mitsunaga
18:00h

19:00h
Oral Presentations 9.
Terapeutics

Chair R Knobler, L Geskins , R Fernández de Misa
18:00h Ther-O-11 Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma.
LW Wilms
18:12h Ther-O-12 Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
GR Roccuzzo
18:24h Ther-O-13 The effect of mogamulizumab on the malignant T cell population – A monocentric retrospective analysis.
JG Gosmann
18:36h Ther-O-14 A Post-hoc Analysis of Clinical Trial Data Shows That Prior Phototherapy Does Not Affect Response to Chlormethine Gel in Patients With Mycosis Fungoides.
C Assaf
18:48h Ther-O-15 TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30.
M Gerlach
19:00h EORTC CLTG General Assembly
19:30h ISCL assembly
19:45h POSTER SESSION 2
20:00h Transfer Hospital – Hotel Only You Atocha
21:00h GALA DINNER

8:30h Transfer Only You Atocha Hotel – Hospital
9:00h

10:00h
INDUSTRY SIMPOSIUM: TAKEDA
Evidence-based Treatment Decisions for Advanced CD30+ Cutaneous T-cell Lymphoma
9:00h Welcome and Introduction
Chalid Assaf, MD, PhD (Chair) Helios Klinikum Krefeld
Krefeld, Germany
9:05h Targeted Treatment of CTCL:
Which Patient Groups Benefit?

Chalid Assaf, MD, PhD
9:20h RWE in Targeted Treatment of
CTCL: Closing the Gap of Clinical Trials

Evangelia Papadavid, MD, PhD National and Kapodistrian University of Athens
Athens, Greece
9:35h Optimizing Treatment Strategy for
Advanced CTCL:
Case Study Analyses

Pietro Quaglino, MD University of Turin Medical School
Turin, Italy
9:50h Audience Q&A
All
10:00h

11:00h
PROCLIPI and QUALITY OF LIFE
Chair: J Scarisbrick, Y Kim, C Jonak
Prognostic Factors in Mycosis Fungoides & Sezary Syndrome: Results from the PROCLIPI Study
10:00h PROCLIPI-O-01 Prognostic Factors in Mycosis Fungoides & Sezary Syndrome: Results from the PROCLIPI Study
JJ Scarisbrick
10:12h PROCLIPI-O-02 What have we learnt about the treatment of advanced stage mycosis fungoides and Sezary syndrome from the PROCLIPI Study?
PQ Quaglino
10:24h QoL-O-01 Update on the development of EORTC/CLTF questionnaires to assess HRQOL in primary cutaneous T-cell and B-cell lymphomas: Phase I
K Molloy
10:36h QoL-O-02 Mogamulizumab-associated rashes may be related to improved therapeutic response in T-cell lymphomas
A Pileri
10:48h QoL-O-03 Quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas
AECS Schirren
11:00h Coffee Break
11:30h

12:30h
Oral Presentations 10.
Epidemiology and Imaging

Chairs: JA Sanches T Estrach
11:30h Epid-O-01 Racial and ethnic factors associated with differences in the receipt of treatments for patients with mycosis fungoides
JBK Brown-Korsah
11:42h Epid-O-02 Lymphomatoid papulosis in pediatric population: preliminary results of a multicenter retrospective cohort study
M Blanchard
11:54h Img-O-01 Baseline radiographic imaging is useful in identifying risk factors for survival and lymph node progression
PBA Allen
12:06h Img-O-02 Lymph node infiltration in mycosis fungoides and Sézary syndrome: ultrasound features descriptive study
VGM Gonzalez
12:30h
INDUSTRY SIMPOSIUM 5
13:30h MEETING CLOSURE
13:30h Lunch
14:00h

16:30h
14:00h Patients’ Symposium
Chair: Susan Thornton, P Ortiz, Almudena Montejo

LW Wilms
Presentation
P Ortiz
14:05h Spanish Association of Patients with Cutaneous Lymphoma (AELIC)
Almudena Montejo, Susana Díaz Guirado
14:15h Spanish Group of Cutaneous Lymphoma
Cristina Muniesa
14:20h Mycosis fungoides and Sézary Syndrome for patients
Mercedes Morillo
14:30h Anaplastic CD30+ large cell lymphoma and lymphomatoid papulosis
Daniel Falkenhain
14:40h Other primary cutaneous T-cell lymphomas for patients
C Postigo
14:50h Primary cutaneous B-cell lymphomas for patients
Eloy Tarín.
15:00h Quality of life of patients with mycosis fungoides. MICADOS STUDY
M Mar Onteniente
15:10h Film presentation.
«Más allá de la piel»
to be confirmed
15:40h Therapeutic Makeup: A fundamental tool to restores self-esteem and quality of life to patients. Live Makeup
Leonor Prieto Cabezas, Scientifc Director Loreal Cosmética Activa Spain Expert in corrective and therapeutic makeup
16:30h Close remarks
Susan Thornton,Almudena Montejo,P Ortiz